Further reading
The source file
This is the one page where the guide opens the filing cabinet. Open what you need. Skip the rest. Links go to government, medical-board, or journal records used for the briefings.
Source filter
LabelsRulesTrials
Product labelcurrent details
Public recordcurrent status
Study summarytrial design
Product labels and approvals
Zepbound prescribing informationThe current federal label is the place for approved uses, warnings, interactions, and product forms.Mounjaro prescribing informationUse this label for the diabetes and heart indications.FDA application recordsBefore a company may sell a new medicine, it must apply to the FDA and be approved. These records list the approvals for Mounjaro and Zepbound, and show that no one has applied to sell a generic tirzepatide.
Access, compounding, and licence checks
FDA concerns about this medicine classThe regulator’s consumer page covers pharmacy-made products, false labels, and source checks.FDA compounding questions and answersA starting point for what compounding is and what FDA review does not cover.Find a state medical boardUse the state board’s own record to check a doctor.Find a state-licensed online pharmacyThe FDA routes readers to state pharmacy licence searches.Medicare weight-medicine programThe federal program page carries the current dates, eligibility path, and copay terms.
Journal records for the main trials
Main obesity trialThe page shows the abstract, a short summary at the top of the article. It says who took part, what tirzepatide was compared with, how long the study ran, and the average weight change.Continuation and withdrawal trialThis record covers what happened after some participants switched to a dummy injection.Head-to-head obesity trialThis is the study that compared tirzepatide with semaglutide, the ingredient in Ozempic and Wegovy.Sleep-apnea trialsThis record covers the two studies behind the sleep-apnea result.
How the guide uses a source
So when a seller quotes a study, check whether the label backs the same claim.
Start with the label. Then read the trial. Stop when the question is answered.
Need one answer? Open one link. Read the page. Close it when the answer is clear.
Ready for the next piece?
Return to the at-a-glance briefing